The Real-world Impact of Dosing of Methadone and Buprenorphine in Retention on Opioid Agonist Therapies in Ukraine

Overview

Journal Addiction

Specialty Psychiatry

Date 2020 May 20

PMID 32428276

Citations 27

Authors

Scott O Farnum

Iuliia Makarenko

Lynn Madden

Alyona Mazhnaya

Ruthanne Marcus

Tanya Prokhorova

Martha J Bojko

Julia Rozanova

Sergii Dvoriak

Zahedsul Islam

Frederick L Altice

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Ukraine's HIV epidemic remains concentrated among opioid-dependent people who inject drugs (PWID) where opioid agonist therapies (OAT) like methadone (MMT) and buprenorphine (BMT) maintenance treatments are the most cost-effective HIV prevention strategies, but remain under-scaled. This study aimed to measure the association between dose and type of OAT prescribed and treatment retention.

Design: Observational longitudinal cohort study.

Participants And Setting: Patients (n = 15 290) prescribed OAT throughout Ukraine from 2004 through 2016.

Measurements: Data were analyzed using time-event strategies to estimate cumulative treatment retention, defined as time to OAT discontinuation. Cumulative retention proportions at 1, 12 and 36 months were assessed for outcomes. Cox regression with log-rank likelihood assessed independent predictors of treatment discontinuation.

Findings: The proportion prescribed high (MMT: > 85 mg; BMT: ≥ 16 mg), medium (MMT: > 40-85 mg; BMT: > 6-15 mg) and low (MMT: ≤ 40 mg; BMT: ≤ 6 mg) dosages was 25, 43 and 32%, respectively. Retention was significantly higher for BMT than MMT both at 12 (89 versus 75%) and 36 months (80 versus 56%). Although dosing levels for BMT did not influence retention, increasing dosages for MMT were significantly associated with higher retention rates at 1 (90, 96, 99%), 12 (59, 78, 91%) and 36 (34, 59, 79%) months, respectively. Independent predictors associated with 12-month OAT discontinuation were medium [adjusted hazard ratio (aHR) = 2.23; 95% confidence limit (CL) = 1.95-2.54] and low (aHR = 4.96; 95% CL = 4.37-5.63) OAT dosage relative to high dosage, male sex (aHR = 1.27; 95% CL = 1.14-1.41), MMT relative to BMT prescription (aHR = 1.57; 95% CL = 1.32-1.87) and receiving OAT in general (aHR = 1.22; 95% CL = 1.02-1.46) or tuberculosis (aHR = 1.43; 95% CL = 1.10-1.85) hospitals, relative to specialty addiction treatment and AIDS center settings. Lower dosages contributed more to dropout especially at 1 month (aHR 3.12; 95% CL = 2.21-4.41 and aHR 7.71; 95% CL = 5.51-10.79 for medium and low dosages, respectively). Younger age was significantly associated with OAT discontinuation only at 36 months (aHR = 1.08; 95% CI = 1.02-1.15).

Conclusions: Higher dosages of opioid agonist therapies, especially for methadone maintenance treatment patients, appear to be associated with higher levels of treatment retention in Ukraine.

Citing Articles

Prescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial.

Mobley A, Wegman M, Bazazi A, Shenoi S, Bromberg D, Ahmad A Int J Drug Policy. 2025; 137:104733.

PMID: 39923270 PMC: 11875876. DOI: 10.1016/j.drugpo.2025.104733.

Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).

Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P Contemp Clin Trials. 2025; 150:107816.

PMID: 39842691 PMC: 11867840. DOI: 10.1016/j.cct.2025.107816.

Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine.

Machavariani E, Dumchev K, Pykalo I, Filippovych M, Ivasiy R, Esserman D Contemp Clin Trials. 2024; 146:107690.

PMID: 39265780 PMC: 11531372. DOI: 10.1016/j.cct.2024.107690.

Historical evolution of healthcare systems of post-soviet Russia, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Armenia, and Azerbaijan: A scoping review.

Semenova Y, Lim L, Salpynov Z, Gaipov A, Jakovljevic M Heliyon. 2024; 10(8):e29550.

PMID: 38655295 PMC: 11036062. DOI: 10.1016/j.heliyon.2024.e29550.

Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia.

Ahmad A, Bromberg D, Shrestha R, Salleh N, Bazazi A, Kamarulzaman A Int J Drug Policy. 2024; 126:104369.

PMID: 38484531 PMC: 11056294. DOI: 10.1016/j.drugpo.2024.104369.

References

Joseph H, Stancliff S, Langrod J . Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000; 67(5-6):347-64. View

Bachireddy C, Soule M, Izenberg J, Dvoryak S, Dumchev K, Altice F . Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug Alcohol Depend. 2013; 134:106-114. PMC: 3865106. DOI: 10.1016/j.drugalcdep.2013.09.020. View

Altice F, Kamarulzaman A, Soriano V, Schechter M, Friedland G . Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010; 376(9738):367-87. PMC: 4855280. DOI: 10.1016/S0140-6736(10)60829-X. View

Schaub M, Subata E, Chtenguelov V, Weiler G, Uchtenhagen A . Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes. Eur Addict Res. 2009; 15(3):157-62. DOI: 10.1159/000217586. View

Malyuta R, Krausz R . No excuses left to delay opioid agonist treatment roll-out. Lancet HIV. 2019; 7(2):e80-e81. DOI: 10.1016/S2352-3018(19)30409-6. View

Polonsky M, Azbel L, Wickersham J, Taxman F, Grishaev E, Dvoryak S . Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend. 2015; 148:47-55. PMC: 4330127. DOI: 10.1016/j.drugalcdep.2014.12.008. View

Ma J, Bao Y, Wang R, Su M, Liu M, Li J . Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018; 24(12):1868-1883. DOI: 10.1038/s41380-018-0094-5. View

Elwyn G, Frosch D, Kobrin S . Implementing shared decision-making: consider all the consequences. Implement Sci. 2016; 11:114. PMC: 4977650. DOI: 10.1186/s13012-016-0480-9. View

Altice F, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S . The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016; 388(10050):1228-48. PMC: 5087988. DOI: 10.1016/S0140-6736(16)30856-X. View

10.

Elwyn G, Fisher E . Higher integrity health care: evidence-based shared decision making. Circ Cardiovasc Qual Outcomes. 2014; 7(6):975-80. DOI: 10.1161/CIRCOUTCOMES.114.000688. View

11.

Bell J, Strang J . Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2019; 87(1):82-88. DOI: 10.1016/j.biopsych.2019.06.020. View

12.

Strain E, Bigelow G, Liebson I, Stitzer M . Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999; 281(11):1000-5. DOI: 10.1001/jama.281.11.1000. View

13.

Feelemyer J, Des Jarlais D, Arasteh K, Abdul-Quader A, Hagan H . Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction. 2013; 109(1):20-32. PMC: 5312702. DOI: 10.1111/add.12303. View

14.

Gryczynski J, Mitchell S, Jaffe J, Kelly S, Myers C, OGrady K . Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat. 2013; 45(3):287-92. PMC: 3714350. DOI: 10.1016/j.jsat.2013.02.008. View

15.

Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko M, Filippovych S . Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug Alcohol Depend. 2016; 165:213-20. PMC: 5094181. DOI: 10.1016/j.drugalcdep.2016.06.011. View

16.

Mukherjee T, Wickersham J, Desai M, Pillai V, Kamarulzaman A, Altice F . Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia. Drug Alcohol Depend. 2016; 164:120-127. PMC: 5592792. DOI: 10.1016/j.drugalcdep.2016.04.037. View

17.

Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B . Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008; 103(9):1484-92. DOI: 10.1111/j.1360-0443.2008.02249.x. View

18.

Walcher S, Koc J, Reichel V, Schlote F, Verthein U, Reimer J . The opiate dosage adequacy scale for identification of the right methadone dose--a prospective cohort study. BMC Pharmacol Toxicol. 2016; 17:15. PMC: 4823862. DOI: 10.1186/s40360-016-0058-9. View

19.

Trujols J, Sinol N, Perez de Los Cobos J . Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment. J Clin Psychopharmacol. 2010; 30(1):95-6. DOI: 10.1097/JCP.0b013e3181c8b439. View

20.

Morozova O, Crawford F, Cohen T, Paltiel A, Altice F . Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction. 2019; 115(3):437-450. PMC: 7015766. DOI: 10.1111/add.14797. View